Innostellar Biotherapeutics Co.,ltd

This is an early-stage study testing a one-time gene therapy called LX101 for people with a rare inherited eye disease that causes progressive vision loss. The goal is to see if the treatment is safe and if it can improve or stabilize vision. Nine participants, aged 6 and older w…

This study is testing whether a one-time gene therapy injection (called LX101) can improve vision in people with a specific inherited retinal disease that causes blindness. The trial involves 30 participants, aged 6 and older, who have vision loss due to mutations in the RPE65 ge…

This study is testing whether a single gene therapy injection (LX102) can help control wet age-related macular degeneration, potentially reducing the need for frequent eye injections. It compares two doses of the experimental therapy against the current standard treatment in 50 p…